Obstetrics & Gynecology · Infectious Disease · 5 h ago
Pregnancy Outcomes After NVX-CoV2373 Vaccination in a South Korean Cohort
A retrospective cohort study using South Korean national health and vaccination records compared pregnancy outcomes after NVX-CoV2373 vaccination with outcomes in unvaccinated women and BNT162b2 recipients. It found no statistically significant differences in preterm birth, congenital structural anomalies or severe postpartum hemorrhage.
- No significant difference in preterm birth was observed.
- Congenital anomalies and severe hemorrhage estimates were imprecise.
- The retrospective analysis included pregnancies ending in live birth.
Researchers used South Korea’s National Health Insurance Service data linked to vaccination records to assess pregnancy outcomes among women aged 20–49 who gave birth between February and December 2022. The retrospective cohort analysis excluded pregnancies with first-trimester SARS-CoV-2 infection and included live births. Propensity-score matching compared 484 NVX-CoV2373 recipients with 1,930 unvaccinated women, and 476 NVX-CoV2373 recipients with 1,497 BNT162b2 recipients. Outcomes were preterm birth, congenital structural anomalies and severe postpartum hemorrhage.
Compared with unvaccinated women, NVX-CoV2373 recipients had no statistically significant difference in preterm birth (adjusted risk ratio [aRR] 0.95, 95% CI 0.75–1.21), congenital structural anomalies (aRR 0.57, 95% CI 0.30–1.09) or severe postpartum hemorrhage (aRR 0.65, 95% CI 0.15–2.90). Comparisons with BNT162b2 recipients were also not statistically significant: aRRs were 1.01 for preterm birth, 0.74 for congenital anomalies and 0.45 for severe postpartum hemorrhage; all confidence intervals included 1.
The findings provide observational evidence on NVX-CoV2373 use during pregnancy, but do not establish equivalence or rule out uncommon harms. The analysis was limited to recorded live births, and estimates for severe postpartum hemorrhage were imprecise. The results address the specified outcomes and do not assess all possible maternal or infant outcomes.
In practice
For pregnant women represented in this South Korean cohort, the study found no statistically significant differences in preterm birth, congenital structural anomalies or severe postpartum hemorrhage after NVX-CoV2373 compared with unvaccinated women or BNT162b2 recipients. These data add observational evidence about NVX-CoV2373 in pregnancy but do not establish equivalent safety or exclude uncommon harms. The analysis included only pregnancies with recorded live births, and confidence intervals—particularly for severe postpartum hemorrhage—were wide; it does not assess every possible maternal or infant outcome.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
The Pediatric Infectious Disease Journal: Risk of Preterm Birth, Congenital Structural Anomalies and Severe Postpartum Hemorrhage After Receipt of NVX-CoV2373 Vaccine During Pregnancy ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.